Climb Bio's budoprutug achieves 38% immunologic remission rate at low dose in Phase 2 pMN trial
Bitget2026/10/24 23:30- Climb Bio presented initial Phase 2 budoprutug results in primary membranous nephropathy at ASN Kidney Week 2026.
- Low-dose treatment reduced disease-associated antibodies and produced immunologic remission, consistent with earlier findings.
- Higher-dose treatment showed deeper B-cell depletion, supporting continued dose evaluation; additional trial data are expected in 2027.
- Both evaluated doses were generally well tolerated, with no treatment-related serious adverse events or treatment discontinuations reported.
- A separate minimal change disease case study presented at the meeting documented three-year steroid-free remission following budoprutug treatment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Cloudflare shares rise as Q3 revenue beats expectations
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
Crypto prices
More
